Cancer

Light-Induced Chemotherapy (‘LICHT’)

Light Induced chemotherapyAt present, all the known anticancer drugs have very serious side-effects.  In order to suppress the toxicity, considerable effort is still being undertaken to deliver these chemotherapeutic drugs selectively to the tumor with minimal or negligible effect on normal tissues and organs.  Previous approaches have relied on exploiting the tumor environment to enable the chemotherapeutic drugs to accumulate at the tumor site.  However, such an approach is not generally applicable or reliable due to large variation in tumor properties.

Daya has invented a new approach, which we refer to as ‘light-induced chemotherapy (LICHT),’ for treating cancers that are readily accessible to light (e.g. colon, lung, uterus, esophagus, etc.).  Essentially, this LICHT technology involves a three-component ensemble in which the anticancer drug is selectively delivered to the tumor site, and is released at that site only using visible light.  It is very important to note that the ensemble inactive if it is not exposed to light.  Also, because the drug is stably attached to the ensemble, there should be no toxicity associated with the anticancer drug itself.  This LICHT technology will be useful not only for the treatment of cancers, but also for bacterial and viral infections as well.

Daya is seeking government grants and/or private equity funding to establish proof of concept.

Triply-Targeted Breast Cancer Chemotherapy

Along with colon, breast cancer remains one of the two largest types of cancers.  Nearly 250,000 new cases of breast cancer in women are diagnosed in the US alone each year, and early detection and treatment of breast cancer is a global health care priority.  Currently, combination therapy using antiestrogen/aromatase inhibitor ‘cocktails’ has been successful in demonstrating greater efficacy than using either of the drugs alone, and is being employed routinely.

The Company is also engaged in breast cancer chemotherapeutic agent based on the concept of triple-targeting, and has actively begun the primary screening of single molecular entity that simultaneously target estrogen receptor, aromatse enzyme, and a transporter protein.

Daya is seeking government grants and/or private equity funding to establish proof of concept.